A Phase 1 interventional study of Ipatasertib and Cobimetinib in Neoplasms, sponsored by Genentech, Inc.. Completed at 5 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-03-28.
Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This open-label, multicenter, Phase Ib dose-escalation study will evaluate the safety, tolerability and pharmacokinetics of oral dosing of GDC-0973 and GDC-0068 administered in combination in patients with locally advanced or metastatic solid tumors. Cohorts of patients will receive multiple ascending doses of GDC-0973 and GDC-0068. Anticipated time on study treatment is until disease progression or unacceptable toxicity occurs.
10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.
This study's enrollment of 67 is above the median of 60 across 7,707 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.
Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.
First submitted after Genentech, Inc. became part of Hoffmann-La Roche.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive cobimetinib (GDC-0973) capsules (at a starting dose of 40 mg) and ipatasertib (GDC-0068) capsules (at a starting dose of 200 mg) from Days 1 to 21 and then 7 days off study drugs from Days 22 to 28 in continuous 28-day cycles. Doses will be increased to identify maximum tolerated dose (MTD) or potential recommended Phase 2 dose (RP2D). Treatment will continue until disease progression, unacceptable toxicity, or any other discontinuation criterion meets.
Drug: Ipatasertib · Drug: Cobimetinib
Participants will receive cobimetinib (GDC-0973) capsules (at a starting dose of 100 mg) on Days 1, 4, 8, 11, 15, and 18 and ipatasertib (GDC-0068) capsules (at a starting dose of 200 mg) from Days 1 to 21 and then 7 days off study drugs from Days 22 to 28 in continuous 28-day cycles. Doses will be increased to identify MTD or potential RP2D. Treatment will continue until disease progression, unacceptable toxicity, or any other discontinuation criterion meets.
Drug: Ipatasertib · Drug: Cobimetinib
Participants will receive cobimetinib (GDC-0973) capsules on Days 1, 4, 8, 11, 15, and 18 and ipatasertib (GDC-0068) capsules from Days 1 to 21 and then 7 days off study drugs from Days 22 to 28 in continuous 28-day cycles, at doses identified as MTD/potential RP2D from Stage 1. Treatment will continue until disease progression, unacceptable toxicity, or any other discontinuation criterion meets. This indication specific cohort will include participants with phosphatase and tensin homolog (PTEN)-loss triple-negative breast cancer and PTEN-loss endometrial carcinoma.
Drug: Ipatasertib · Drug: Cobimetinib
multiple doses
Also known as: GDC-0068
multiple doses
Also known as: GDC-0973
Number of Participants With Dose Limiting Toxicities (DLTs)
DLT is defined as 1 of the following toxicities considered by the investigator to be possibly related to study drugs: a) Grade (G) ≥3 febrile neutropenia, b) G ≥4 neutropenia (absolute neutrophil count \[ANC\] \<500/ microliter \[μL\]) lasting \>5 days , c) G ≥4 thrombocytopenia lasting \>2 days, d) G ≥4 anemia, e) G ≥3 elevation of total bilirubin or hepatic transaminase or alkaline phosphatase (ALP) lasting \>3 days, f) Hepatic transaminases \>3 × Upper Limit of Normal (ULN) and an increase in total bilirubin \>2 × ULN without any findings of cholestasis and in the absence of other contributory factors, g) G ≥2 visual changes that do not resolve to baseline within 14 days, h) 1 episode of fasting G 4 hyperglycemia or 3 episodes of fasting, i) G 3 hyperglycemia on separate days within 7 days, j) G ≥4 fasting hypercholesterolemia or triglyceridemia for ≥2 weeks, k) G ≥3 nausea, vomiting, or diarrhea despite maximal supportive medications lasting for ≥3 days.
Time frame: Cycle 1 (28 Days)
Number of DLTs Categorized as Per the Nature
DLT is defined as 1 of the following toxicities considered by the investigator to be possibly related to study drugs: a) G ≥3 febrile neutropenia, b) G ≥4 neutropenia (ANC \<500/μL) lasting \>5 days , c) G ≥4 thrombocytopenia lasting \>2 days, d) G ≥4 anemia, e) G ≥3 elevation of total bilirubin or hepatic transaminase or ALP lasting \>3 days, f) Hepatic transaminases \>3 × ULN and an increase in total bilirubin \>2 × ULN without any findings of cholestasis and in the absence of other contributory factors, g) G ≥2 visual changes that do not resolve to baseline within 14 days, h) 1 episode of fasting G 4 hyperglycemia or 3 episodes of fasting, i) G 3 hyperglycemia on separate days within 7 days, j) G ≥4 fasting hypercholesterolemia or triglyceridemia for ≥2 weeks, k) G ≥3 nausea, vomiting, or diarrhea despite maximal supportive medications lasting for ≥3 days. Hematologic, Hepatic and non-hematologic and non-hepatic DLT categories were to be reported.
Time frame: Cycle 1 (28 Days)
Maximum Tolerated Doses (MTDs) in Combination of Cobimetinib and Ipatasertib During Dose-Escalation Stage 1
An adverse event (AE) is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of an investigational medicinal product (IMP) or other protocol-imposed intervention, regardless of attribution. On the basis of AEs that did not meet protocol-defined DLT criteria (defined in Outcome measure 1) but indicated intolerability of a given dose combination, the combination MTDs were determined (as per investigator) during Stage 1 of the study.
Time frame: Cycle 1 (28 Days)
Number of Participants With At Least One AE Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version (V) 4.0
AE was defined in Outcome Measure 3. AEs were graded as per NCI CTCAE V 4.0 as follows: G 1: asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; G 2: minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental activities of daily living (ADL) (instrumental ADL refers to preparing meals, shopping for groceries or clothes, using the telephone, managing money and others); G 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated, disabling, limiting self care ADL (refers to bathing, dressing and undressing, feeding self, using the toilet, taking medications, and not bedridden); G 4: Life-threatening consequences, urgent intervention indicated; G 5: Death related to AE. If a participant had multiple events of different grades, the highest grade that occurred in that participant was counted.
Time frame: From Baseline up to 30 days after the last dose of study treatment or until initiation of another anticancer treatment whichever occurred first (Up to 33 months)
Area Under Concentration-Time Curve From Time Zero to Last Measurable Concentration After Dose [AUC0-Last] of Ipatasertib and Cobimetinib on Day 1 and Day 15
Time frame: Predose (0 hour), 1, 2, 4, 6 and 24 hours postdose on Day 1 and Day 15 of Cycle 1
Maximum Plasma Concentration (Cmax) of Ipatasertib and Cobimetinib on Day 1 and Day 15
Time frame: Predose (0 hour), 1, 2, 4, 6 and 24 hours postdose on Day 1 and Day 15 of Cycle 1
Time Taken to Reach Cmax (Tmax) of Ipatasertib and Cobimetinib on Day 1 and Day 15
Time frame: Predose (0 hour), 1, 2, 4, 6 and 24 hours postdose on Day 1 and Day 15 of Cycle 1
Last Measurable Concentration (Clast) of Ipatasertib and Cobimetinib on Day 1 and Day 15
Time frame: Predose (0 hour), 1, 2, 4, 6 and 24 hours postdose on Day 1 and Day 15 of Cycle 1
Number of Participants With Objective Response of Complete Response (CR) or Partial Response (PR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)
RECIST v1.1 (for measurable disease), CR: disappearance of all target lesions, reduction in short axis \<10 millimeters in pathological lymph nodes (target and non-target lesions); PR: at least a 30 percent (%) decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter. Responses were confirmed by repeat assessments ≥4 weeks after initial documentation.
Time frame: Screening, Days 21-28 of Cycle 2, Day 25 (± 3 days) of Cycle 4 and every 8 weeks thereafter till study completion (Up to 33 months)
Duration of Objective Response for Participants With Measurable Disease According to RECIST v1.1
Duration of response, defined as the time from first occurrence of a documented objective response until the time of disease progression, as determined by investigator review of tumor assessments using RECIST 1.1, or death from any cause during the study (i.e., within 30 days after the last dose of study treatment).
Time frame: Screening, Days 21-28 of Cycle 2, Day 25 (± 3 days) of Cycle 4 and every 8 weeks thereafter till study completion (Up to 33 months)
Progression-Free Survival (PFS) Time for Participants With Measurable Disease According to RECIST v1.1
PFS is defined as the time from study treatment initiation to the first occurrence of disease progression, as determined by investigator review of tumor assessments using RECIST 1.1, or death from any cause during the study (i.e., within 30 days after the last dose of study treatment).
Time frame: Screening, Days 21-28 of Cycle 2, Day 25 (± 3 days) of Cycle 4 and every 8 weeks thereafter till study completion (Up to 33 months)
| Milestone | DEC Arm A: 40 mg Cobimetinib + 200 mg Ipatasertib | DEC Arm A: 60 mg Cobimetinib + 200 mg Ipatasertib | DEC Arm A: 60 mg Cobimetinib + 300 mg Ipatasertib | DEC Arm A: 40 mg Cobimetinib + 400 mg Ipatasertib | DEC Arm B: 100 mg Cobimetinib + 200 mg Ipatasertib | DEC Arm B: 125 mg Cobimetinib + 200 mg Ipatasertib | DEC Arm B: 125 mg Cobimetinib + 400 mg Ipatasertib | DEC Arm B: 150 mg Cobimetinib + 300 mg Ipatasertib | DEC Arm B: 175 mg Cobimetinib + 200 mg Ipatasertib | DEC Arm B: 150 mg Cobimetinib + 200 mg Ipatasertib | DEC Arm B: 100 mg Cobimetinib + 400 mg Ipatasertib | Endometrial Carcinoma: 140 mg Cobimetinib + 300 mg Ipatasertib | Breast Cancer: 140 mg Cobimetinib + 300 mg Ipatasertib |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 3 | 7 | 3 | 4 | 4 | 4 | 3 | 7 | 3 | 7 | 3 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 3 | 7 | 3 | 4 | 4 | 4 | 3 | 7 | 3 | 7 | 3 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Death | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Non compliance | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Progression of disease | 2 | 6 | 2 | 1 | 2 | 4 | 1 | 7 | 2 | 5 | 3 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 2 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 |
| Milestone | DEC Arm A: 40 mg Cobimetinib + 200 mg Ipatasertib | DEC Arm A: 60 mg Cobimetinib + 200 mg Ipatasertib | DEC Arm A: 60 mg Cobimetinib + 300 mg Ipatasertib | DEC Arm A: 40 mg Cobimetinib + 400 mg Ipatasertib | DEC Arm B: 100 mg Cobimetinib + 200 mg Ipatasertib | DEC Arm B: 125 mg Cobimetinib + 200 mg Ipatasertib | DEC Arm B: 125 mg Cobimetinib + 400 mg Ipatasertib | DEC Arm B: 150 mg Cobimetinib + 300 mg Ipatasertib | DEC Arm B: 175 mg Cobimetinib + 200 mg Ipatasertib | DEC Arm B: 150 mg Cobimetinib + 200 mg Ipatasertib | DEC Arm B: 100 mg Cobimetinib + 400 mg Ipatasertib | Endometrial Carcinoma: 140 mg Cobimetinib + 300 mg Ipatasertib | Breast Cancer: 140 mg Cobimetinib + 300 mg Ipatasertib |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 14 | 5 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 14 | 5 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 |
| Withdrew: Progression of disease | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12 | 4 |
DLT is defined as 1 of the following toxicities considered by the investigator to be possibly related to study drugs: a) Grade (G) ≥3 febrile neutropenia, b) G ≥4 neutropenia (absolute neutrophil count \[ANC\] \<500/ microliter \[μL\]) lasting \>5 days , c) G ≥4 thrombocytopenia lasting \>2 days, d) G ≥4 anemia, e) G ≥3 elevation of total bilirubin or hepatic transaminase or alkaline phosphatase (ALP) lasting \>3 days, f) Hepatic transaminases \>3 × Upper Limit of Normal (ULN) and an increase in total bilirubin \>2 × ULN without any findings of cholestasis and in the absence of other contributory factors, g) G ≥2 visual changes that do not resolve to baseline within 14 days, h) 1 episode of fasting G 4 hyperglycemia or 3 episodes of fasting, i) G 3 hyperglycemia on separate days within 7 days, j) G ≥4 fasting hypercholesterolemia or triglyceridemia for ≥2 weeks, k) G ≥3 nausea, vomiting, or diarrhea despite maximal supportive medications lasting for ≥3 days.
| participants | DEC Arm A: 40 mg Cobimetinib + 200 mg Ipatasertib | DEC Arm A: 60 mg Cobimetinib + 200 mg Ipatasertib | DEC Arm A: 60 mg Cobimetinib + 300 mg Ipatasertib | DEC Arm A: 40 mg Cobimetinib + 400 mg Ipatasertib | DEC Arm B: 100 mg Cobimetinib + 200 mg Ipatasertib | DEC Arm B: 125 mg Cobimetinib + 200 mg Ipatasertib | DEC Arm B: 125 mg Cobimetinib + 400 mg Ipatasertib | DEC Arm B: 150 mg Cobimetinib + 300 mg Ipatasertib | DEC Arm B: 175 mg Cobimetinib + 200 mg Ipatasertib | DEC Arm B: 150 mg Cobimetinib + 200 mg Ipatasertib | DEC Arm B: 100 mg Cobimetinib + 400 mg Ipatasertib |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Dose Limiting Toxicities (DLTs) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
DLT is defined as 1 of the following toxicities considered by the investigator to be possibly related to study drugs: a) G ≥3 febrile neutropenia, b) G ≥4 neutropenia (ANC \<500/μL) lasting \>5 days , c) G ≥4 thrombocytopenia lasting \>2 days, d) G ≥4 anemia, e) G ≥3 elevation of total bilirubin or hepatic transaminase or ALP lasting \>3 days, f) Hepatic transaminases \>3 × ULN and an increase in total bilirubin \>2 × ULN without any findings of cholestasis and in the absence of other contributory factors, g) G ≥2 visual changes that do not resolve to baseline within 14 days, h) 1 episode of fasting G 4 hyperglycemia or 3 episodes of fasting, i) G 3 hyperglycemia on separate days within 7 days, j) G ≥4 fasting hypercholesterolemia or triglyceridemia for ≥2 weeks, k) G ≥3 nausea, vomiting, or diarrhea despite maximal supportive medications lasting for ≥3 days. Hematologic, Hepatic and non-hematologic and non-hepatic DLT categories were to be reported.
No measurements were reported for this outcome.
An adverse event (AE) is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of an investigational medicinal product (IMP) or other protocol-imposed intervention, regardless of attribution. On the basis of AEs that did not meet protocol-defined DLT criteria (defined in Outcome measure 1) but indicated intolerability of a given dose combination, the combination MTDs were determined (as per investigator) during Stage 1 of the study.
| milligrams | Stage 1 DECs |
|---|---|
| Arm A Cobimetinib dose | 60 |
| Arm A Ipatasertib dose | 200 |
| Arm B Cobimetinib dose | 150 |
| Arm B Ipatasertib dose | 300 |
AE was defined in Outcome Measure 3. AEs were graded as per NCI CTCAE V 4.0 as follows: G 1: asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; G 2: minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental activities of daily living (ADL) (instrumental ADL refers to preparing meals, shopping for groceries or clothes, using the telephone, managing money and others); G 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated, disabling, limiting self care ADL (refers to bathing, dressing and undressing, feeding self, using the toilet, taking medications, and not bedridden); G 4: Life-threatening consequences, urgent intervention indicated; G 5: Death related to AE. If a participant had multiple events of different grades, the highest grade that occurred in that participant was counted.
| participants | DECs and Expansion Cohorts |
|---|---|
| Grade 1 (G 1) | 4 |
| Grade 2 (G 2) | 15 |
| Grade 3 (G 3) | 36 |
| Grade 4 (G 4) | 1 |
| Grade 5 (G 5) | 10 |
| nanograms*hours/milliliter (ng*h/mL) | DEC Arm A: 40 mg Cobimetinib + 200 mg Ipatasertib | DEC Arm A: 60 mg Cobimetinib + 200 mg Ipatasertib | DEC Arm A: 60 mg Cobimetinib + 300 mg Ipatasertib | DEC Arm A: 40 mg Cobimetinib + 400 mg Ipatasertib | DEC Arm B: 100 mg Cobimetinib + 200 mg Ipatasertib | DEC Arm B: 125 mg Cobimetinib + 200 mg Ipatasertib | DEC Arm B: 125 mg Cobimetinib + 400 mg Ipatasertib | DEC Arm B: 150 mg Cobimetinib + 300 mg Ipatasertib | DEC Arm B: 175 mg Cobimetinib + 200 mg Ipatasertib | DEC Arm B: 150 mg Cobimetinib + 200 mg Ipatasertib | DEC Arm B: 100 mg Cobimetinib + 400 mg Ipatasertib | Endometrial Carcinoma: 140 mg Cobimetinib + 300 mg Ipatasertib | Breast Cancer: 140 mg Cobimetinib + 300 mg Ipatasertib |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ipatasertib Day 1 (n=3,7,1,4,4,4,3,5,2,6,2,14,5) | 688 ± 106 | 538 ± 33.8 | 1760 ± NA | 2170 ± 74.9 | 255 ± 203 | 956 ± 43.5 | 1420 ± 46.4 | 790 ± 78.8 | 838 ± 239 | 424 ± 67.9 | 2030 ± 46.4 | 1450 ± 48.7 | 1540 ± 11.3 |
| Ipatasertib Day 15 (n=3,6,2,1,4,3,1,6,2,5,2,7,2) | 703 ± 40.8 | 781 ± 20.7 | 2440 ± 45.2 | 1750 ± NA | 599 ± 133 | 1760 ± 62.3 | 2230 ± NA | 1260 ± 85.2 | 668 ± 148 | 866 ± 58.1 | 3390 ± 9.70 | 1070 ± 65.2 | 1270 ± 13.3 |
| Cobimetinib Day 1 (n=3,7,1,4,4,4,3,5,2,6,2,14,5) | 1500 ± 320 | 1130 ± 68.6 | 5050 ± NA | 1920 ± 87.8 | 3740 ± 139 | 5580 ± 54.4 | 2690 ± 50.7 | 2710 ± 60.7 | 13600 ± 111 | 3270 ± 89.2 | 4330 ± 39.3 | 11400 ± 64.1 | 10800 ± 41.0 |
| Cobimetinib Day 15 (n=3,6,2,1,4,3,1,6,1,5,2,7,2) | 3250 ± 223 | 3260 ± 48.6 | 7080 ± 91.1 | 2500 ± NA | 3230 ± 96.8 | 8140 ± 5.65 | 4400 ± NA | 4970 ± 65.5 | 8570 ± NA | 3980 ± 111 | 6830 ± 38.4 | 8880 ± 64.8 | 1480 ± 10800 |
| nanograms per milliliter (ng/mL) | DEC Arm A: 40 mg Cobimetinib + 200 mg Ipatasertib | DEC Arm A: 60 mg Cobimetinib + 200 mg Ipatasertib | DEC Arm A: 60 mg Cobimetinib + 300 mg Ipatasertib | DEC Arm A: 40 mg Cobimetinib + 400 mg Ipatasertib | DEC Arm B: 100 mg Cobimetinib + 200 mg Ipatasertib | DEC Arm B: 125 mg Cobimetinib + 200 mg Ipatasertib | DEC Arm B: 125 mg Cobimetinib + 400 mg Ipatasertib | DEC Arm B: 150 mg Cobimetinib + 300 mg Ipatasertib | DEC Arm B: 175 mg Cobimetinib + 200 mg Ipatasertib | DEC Arm B: 150 mg Cobimetinib + 200 mg Ipatasertib | DEC Arm B: 100 mg Cobimetinib + 400 mg Ipatasertib | Endometrial Carcinoma: 140 mg Cobimetinib + 300 mg Ipatasertib | Breast Cancer: 140 mg Cobimetinib + 300 mg Ipatasertib |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ipatasertib Day 1 (n=3,7,1,4,4,4,3,5,2,6,2,14,5) | 137 ± 244 | 97.1 ± 92.2 | 300 ± NA | 336 ± 118 | 42.9 ± 560 | 156 ± 32.8 | 329 ± 104 | 141 ± 34.3 | 99.9 ± 254 | 95.8 ± 57.1 | 262 ± 122 | 268 ± 48.3 | 374 ± 48.2 |
| Ipatasertib Day 15 (n=3,6,2,1,4,3,1,6,2,5,2,7,2) | 94.5 ± 55.0 | 130 ± 47.1 | 386 ± 58.4 | 137 ± NA | 86.9 ± 237 | 165 ± 33.9 | 441 ± NA | 170 ± 64.4 | 72.9 ± 200 | 114 ± 53.9 | 450 ± 16.9 | 149 ± 113 | 156 ± 12.7 |
| Cobimetinib Day 1 (n=3,7,1,4,4,4,3,5,2,6,2,14,5) | 134 ± 333 | 78.6 ± 73.2 | 312 ± NA | 109 ± 85.4 | 259 ± 192 | 405 ± 45.9 | 192 ± 50.3 | 220 ± 64.9 | 1040 ± 151 | 262 ± 59.9 | 249 ± 46.0 | 799 ± 55.8 | 840 ± 56.6 |
| Cobimetinib Day 15 (n=3,6,2,1,4,3,1,6,1,5,2,7,2) | 222 ± 182 | 215 ± 61.4 | 407 ± 72.6 | 121 ± NA | 217 ± 135 | 511 ± 14.6 | 376 ± NA | 320 ± 64.5 | 481 ± NA | 253 ± 103 | 420 ± 41.4 | 704 ± 75.2 | 84.2 ± 7940 |
| hours | DEC Arm A: 40 mg Cobimetinib + 200 mg Ipatasertib | DEC Arm A: 60 mg Cobimetinib + 200 mg Ipatasertib | DEC Arm A: 60 mg Cobimetinib + 300 mg Ipatasertib | DEC Arm A: 40 mg Cobimetinib + 400 mg Ipatasertib | DEC Arm B: 100 mg Cobimetinib + 200 mg Ipatasertib | DEC Arm B: 125 mg Cobimetinib + 200 mg Ipatasertib | DEC Arm B: 125 mg Cobimetinib + 400 mg Ipatasertib | DEC Arm B: 150 mg Cobimetinib + 300 mg Ipatasertib | DEC Arm B: 175 mg Cobimetinib + 200 mg Ipatasertib | DEC Arm B: 150 mg Cobimetinib + 200 mg Ipatasertib | DEC Arm B: 100 mg Cobimetinib + 400 mg Ipatasertib | Endometrial Carcinoma: 140 mg Cobimetinib + 300 mg Ipatasertib | Breast Cancer: 140 mg Cobimetinib + 300 mg Ipatasertib |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ipatasertib Day 1 (n=3,7,1,4,4,4,3,5,2,6,2,14,5) | 1.03 (1.00 to 1.05) | 1.02 (0.92 to 4.08) | 1.00 (NA to NA) | 1.04 (1.00 to 4.08) | 1.00 (0.92 to 4.78) | 3.04 (1.00 to 4.13) | 1.00 (0.90 to 2.40) | 2.00 (1.92 to 4.00) | 3.17 (2.08 to 4.25) | 1.08 (1.00 to 2.00) | 1.52 (1.00 to 2.03) | 1.47 (0.95 to 4.00) | 1.00 (1.00 to 1.00) |
| Ipatasertib Day 15 (n=3,6,2,1,4,3,1,6,2,5,2,7,2) | 2.03 (0.95 to 2.25) | 1.03 (1.00 to 3.83) | 1.04 (1.00 to 1.08) | 6.05 (NA to NA) | 1.04 (1.00 to 1.15) | 1.00 (1.00 to 2.00) | 1.00 (NA to NA) | 1.19 (1.00 to 6.00) | 1.57 (1.00 to 2.13) | 1.00 (0.92 to 4.08) | 0.98 (0.93 to 1.02) | 1.08 (0.92 to 3.58) | 0.97 (0.93 to 1.00) |
| Cobimetinib Day 1 (n=3,7,1,4,4,4,3,5,2,6,2,14,5) | 2.00 (2.00 to 4.00) | 3.97 (1.92 to 24.0) | 2.05 (NA to NA) | 3.83 (2.02 to 5.95) | 3.04 (2.00 to 6.00) | 3.03 (2.00 to 6.00) | 4.05 (4.00 to 4.27) | 4.00 (2.00 to 23.9) | 24.0 (22.0 to 26.0) | 3.91 (2.00 to 4.25) | 5.92 (5.83 to 6.00) | 3.08 (1.00 to 24.4) | 2.08 (2.00 to 5.42) |
| Cobimetinib Day 15 (n=3,6,2,1,4,3,1,6,1,5,2,7,2) | 2.25 (2.00 to 4.00) | 3.92 (2.08 to 4.00) | 3.01 (2.00 to 4.02) | 6.05 (NA to NA) | 4.78 (1.15 to 5.97) | 4.03 (4.00 to 24.2) | 1.88 (NA to NA) | 4.06 (2.25 to 23.7) | 5.92 (NA to NA) | 4.00 (0.00 to 5.58) | 13.1 (2.00 to 24.1) | 2.00 (1.00 to 24.3) | 1.96 (1.92 to 2.00) |
| ng/mL | DEC Arm A: 40 mg Cobimetinib + 200 mg Ipatasertib | DEC Arm A: 60 mg Cobimetinib + 200 mg Ipatasertib | DEC Arm A: 60 mg Cobimetinib + 300 mg Ipatasertib | DEC Arm A: 40 mg Cobimetinib + 400 mg Ipatasertib | DEC Arm B: 100 mg Cobimetinib + 200 mg Ipatasertib | DEC Arm B: 125 mg Cobimetinib + 200 mg Ipatasertib | DEC Arm B: 125 mg Cobimetinib + 400 mg Ipatasertib | DEC Arm B: 150 mg Cobimetinib + 300 mg Ipatasertib | DEC Arm B: 175 mg Cobimetinib + 200 mg Ipatasertib | DEC Arm B: 150 mg Cobimetinib + 200 mg Ipatasertib | DEC Arm B: 100 mg Cobimetinib + 400 mg Ipatasertib | Endometrial Carcinoma: 140 mg Cobimetinib + 300 mg Ipatasertib | Breast Cancer: 140 mg Cobimetinib + 300 mg Ipatasertib |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ipatasertib Day 1 (n=3,7,1,4,4,4,3,5,2,6,2,14,5) | 6.18 ± 4.90 | 6.07 ± 1.99 | 23.7 ± NA | 25.1 ± 11.3 | 4.32 ± 2.60 | 13.4 ± 8.29 | 15.2 ± 5.15 | 7.05 ± 11.60 | 18.2 ± 16.2 | 6.00 ± 4.18 | 30.0 ± 5.66 | 18.0 ± 10.1 | 15.4 ± 6.38 |
| Ipatasertib Day 15 (n=3,6,2,1,4,3,1,6,2,5,2,7,2) | 14.1 ± 4.54 | 11.6 ± 1.79 | 38.0 ± 14.5 | 30.6 ± NA | 12.8 ± 6.85 | 30.6 ± 22.2 | 39.3 ± NA | 21.90 ± 45.50 | 13.0 ± 7.66 | 16.9 ± 10.9 | 54.7 ± 15.5 | 20.7 ± 12.1 | 14.5 ± 8.68 |
| Cobimetinib Day 1 (n=3,7,1,4,4,4,3,5,2,6,2,14,5) | 79.4 ± 119 | 35.9 ± 10.5 | 150 ± NA | 71.9 ± 44.0 | 122 ± 76.5 | 204 ± 172 | 72.6 ± 30.7 | 145 ± 159 | 1280 ± 1120 | 125 ± 127 | 160 ± 17.7 | 386 ± 237 | 268 ± 146 |
| Cobimetinib Day 15 (n=3,6,2,1,4,3,1,6,1,5,2,7,2) | 228 ± 319 | 105 ± 58.3 | 251 ± 192 | 93.8 ± NA | 123 ± 70.2 | 294 ± 158 | 127 ± NA | 186 ± 116 | 283 ± NA | 204 ± 254 | 280 ± 53.0 | 299 ± 172 | 227 ± 316 |
RECIST v1.1 (for measurable disease), CR: disappearance of all target lesions, reduction in short axis \<10 millimeters in pathological lymph nodes (target and non-target lesions); PR: at least a 30 percent (%) decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter. Responses were confirmed by repeat assessments ≥4 weeks after initial documentation.
| participants | DEC Arm A: 40 mg Cobimetinib + 200 mg Ipatasertib | DEC Arm A: 60 mg Cobimetinib + 200 mg Ipatasertib | DEC Arm A: 60 mg Cobimetinib + 300 mg Ipatasertib | DEC Arm A: 40 mg Cobimetinib + 400 mg Ipatasertib | DEC Arm B: 100 mg Cobimetinib + 200 mg Ipatasertib | DEC Arm B: 125 mg Cobimetinib + 200 mg Ipatasertib | DEC Arm B: 125 mg Cobimetinib + 400 mg Ipatasertib | DEC Arm B: 150 mg Cobimetinib + 300 mg Ipatasertib | DEC Arm B: 175 mg Cobimetinib + 200 mg Ipatasertib | DEC Arm B: 150 mg Cobimetinib + 200 mg Ipatasertib | DEC Arm B: 100 mg Cobimetinib + 400 mg Ipatasertib | Endometrial Carcinoma: 140 mg Cobimetinib + 300 mg Ipatasertib | Breast Cancer: 140 mg Cobimetinib + 300 mg Ipatasertib |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Objective Response of Complete Response (CR) or Partial Response (PR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
Duration of response, defined as the time from first occurrence of a documented objective response until the time of disease progression, as determined by investigator review of tumor assessments using RECIST 1.1, or death from any cause during the study (i.e., within 30 days after the last dose of study treatment).
No measurements were reported for this outcome.
PFS is defined as the time from study treatment initiation to the first occurrence of disease progression, as determined by investigator review of tumor assessments using RECIST 1.1, or death from any cause during the study (i.e., within 30 days after the last dose of study treatment).
No measurements were reported for this outcome.
Collected over From Baseline up to 30 days after the last dose of study treatment or until initiation of another anticancer treatment whichever occurred first (Up to 33 months). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| DEC Arm A: 40 mg Cobimetinib + 200 mg Ipatasertib | — | 1/3 (33.3%) | 3/3 (100%) |
| DEC Arm A: 60 mg Cobimetinib + 200 mg Ipatasertib | — | 2/7 (28.6%) | 7/7 (100%) |
| DEC Arm A: 60 mg Cobimetinib + 300 mg Ipatasertib | — | 0/3 (0%) | 3/3 (100%) |
| DEC Arm A: 40 mg Cobimetinib + 400 mg Ipatasertib | — | 2/4 (50%) | 4/4 (100%) |
| DEC Arm B: 100 mg Cobimetinib + 200 mg Ipatasertib | — | 1/4 (25%) | 4/4 (100%) |
| DEC Arm B: 125 mg Cobimetinib + 200 mg Ipatasertib | — | 3/4 (75%) | 4/4 (100%) |
| DEC Arm B: 125 mg Cobimetinib + 400 mg Ipatasertib | — | 1/3 (33.3%) | 3/3 (100%) |
| DEC Arm B: 150 mg Cobimetinib + 300 mg Ipatasertib | — | 1/7 (14.3%) | 7/7 (100%) |
| DEC Arm B: 175 mg Cobimetinib + 200 mg Ipatasertib | — | 0/3 (0%) | 3/3 (100%) |
| DEC Arm B: 150 mg Cobimetinib + 200 mg Ipatasertib | — | 2/6 (33.3%) | 6/6 (100%) |
| DEC Arm B: 100 mg Cobimetinib + 400 mg Ipatasertib | — | 2/3 (66.7%) | 3/3 (100%) |
| Endometrial Carcinoma: 140 mg Cobimetinib + 300 mg Ipatasertib | — | 10/14 (71.4%) | 14/14 (100%) |
| Breast Cancer: 140 mg Cobimetinib + 300 mg Ipatasertib | — | 2/5 (40%) | 5/5 (100%) |
| Event | DEC Arm A: 40 mg Cobimetinib + 200 mg Ipatasertib | DEC Arm A: 60 mg Cobimetinib + 200 mg Ipatasertib | DEC Arm A: 60 mg Cobimetinib + 300 mg Ipatasertib | DEC Arm A: 40 mg Cobimetinib + 400 mg Ipatasertib | DEC Arm B: 100 mg Cobimetinib + 200 mg Ipatasertib | DEC Arm B: 125 mg Cobimetinib + 200 mg Ipatasertib | DEC Arm B: 125 mg Cobimetinib + 400 mg Ipatasertib | DEC Arm B: 150 mg Cobimetinib + 300 mg Ipatasertib | DEC Arm B: 175 mg Cobimetinib + 200 mg Ipatasertib | DEC Arm B: 150 mg Cobimetinib + 200 mg Ipatasertib | DEC Arm B: 100 mg Cobimetinib + 400 mg Ipatasertib | Endometrial Carcinoma: 140 mg Cobimetinib + 300 mg Ipatasertib | Breast Cancer: 140 mg Cobimetinib + 300 mg Ipatasertib |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abdominal PainGastrointestinal disorders | 0/3 | 0/7 | 0/3 | 0/4 | 0/4 | 0/4 | 0/3 | 0/7 | 0/3 | 0/6 | 1/3 | 0/14 | 0/5 |
| Gastrointestinal HaemorrhageGastrointestinal disorders | 0/3 | 0/7 | 0/3 | 0/4 | 0/4 | 0/4 | 1/3 | 0/7 | 0/3 | 0/6 | 0/3 | 0/14 | 0/5 |
| Intestinal ObstructionGastrointestinal disorders | 1/3 | 0/7 | 0/3 | 0/4 | 0/4 | 0/4 | 0/3 | 0/7 | 0/3 | 0/6 | 0/3 | 0/14 | 0/5 |
| Bile Duct ObstructionHepatobiliary disorders | 0/3 | 1/7 | 0/3 | 0/4 | 0/4 | 0/4 | 0/3 | 0/7 | 0/3 | 0/6 | 1/3 | 0/14 | 0/5 |
| Hip FractureInjury, poisoning and procedural complications | 0/3 | 0/7 | 0/3 | 0/4 | 0/4 | 0/4 | 0/3 | 0/7 | 0/3 | 0/6 | 1/3 | 0/14 | 0/5 |
| DehydrationMetabolism and nutrition disorders | 0/3 | 0/7 | 0/3 | 1/4 | 0/4 | 0/4 | 0/3 | 0/7 | 0/3 | 0/6 | 1/3 | 2/14 | 0/5 |
| HyperkalaemiaMetabolism and nutrition disorders | 0/3 | 0/7 | 0/3 | 0/4 | 0/4 | 0/4 | 1/3 | 0/7 | 0/3 | 0/6 | 0/3 | 0/14 | 0/5 |
| Mental Status ChangesPsychiatric disorders | 0/3 | 0/7 | 0/3 | 0/4 | 0/4 | 0/4 | 0/3 | 0/7 | 0/3 | 0/6 | 1/3 | 0/14 | 0/5 |
| Renal Failure AcuteRenal and urinary disorders | 0/3 | 0/7 | 0/3 | 1/4 | 1/4 | 0/4 | 1/3 | 0/7 | 0/3 | 0/6 | 0/3 | 1/14 | 0/5 |
| Atrial FibrillationCardiac disorders | 0/3 | 0/7 | 0/3 | 0/4 | 1/4 | 0/4 | 0/3 | 0/7 | 0/3 | 0/6 | 0/3 | 0/14 | 0/5 |
| Event | DEC Arm A: 40 mg Cobimetinib + 200 mg Ipatasertib | DEC Arm A: 60 mg Cobimetinib + 200 mg Ipatasertib | DEC Arm A: 60 mg Cobimetinib + 300 mg Ipatasertib | DEC Arm A: 40 mg Cobimetinib + 400 mg Ipatasertib | DEC Arm B: 100 mg Cobimetinib + 200 mg Ipatasertib | DEC Arm B: 125 mg Cobimetinib + 200 mg Ipatasertib | DEC Arm B: 125 mg Cobimetinib + 400 mg Ipatasertib | DEC Arm B: 150 mg Cobimetinib + 300 mg Ipatasertib | DEC Arm B: 175 mg Cobimetinib + 200 mg Ipatasertib | DEC Arm B: 150 mg Cobimetinib + 200 mg Ipatasertib | DEC Arm B: 100 mg Cobimetinib + 400 mg Ipatasertib | Endometrial Carcinoma: 140 mg Cobimetinib + 300 mg Ipatasertib | Breast Cancer: 140 mg Cobimetinib + 300 mg Ipatasertib |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 3/3 | 6/7 | 3/3 | 4/4 | 4/4 | 3/4 | 3/3 | 7/7 | 3/3 | 4/6 | 3/3 | 14/14 | 5/5 |
| NauseaGastrointestinal disorders | 2/3 | 4/7 | 2/3 | 4/4 | 3/4 | 2/4 | 1/3 | 4/7 | 1/3 | 6/6 | 3/3 | 11/14 | 4/5 |
| VomitingGastrointestinal disorders | 2/3 | 4/7 | 2/3 | 4/4 | 3/4 | 3/4 | 2/3 | 3/7 | 2/3 | 5/6 | 3/3 | 12/14 | 3/5 |
| FatigueGeneral disorders | 3/3 | 3/7 | 1/3 | 2/4 | 2/4 | 1/4 | 2/3 | 4/7 | 1/3 | 4/6 | 3/3 | 5/14 | 1/5 |
| Decreased AppetiteMetabolism and nutrition disorders | 1/3 | 4/7 | 0/3 | 1/4 | 2/4 | 2/4 | 0/3 | 0/7 | 1/3 | 1/6 | 3/3 | 7/14 | 1/5 |
| Dermatitis AcneiformSkin and subcutaneous tissue disorders | 0/3 | 2/7 | 2/3 | 1/4 | 1/4 | 2/4 | 1/3 | 7/7 | 3/3 | 5/6 | 1/3 | 8/14 | 2/5 |
| AstheniaGeneral disorders | 0/3 | 0/7 | 0/3 | 1/4 | 1/4 | 2/4 | 0/3 | 0/7 | 0/3 | 0/6 | 0/3 | 4/14 | 4/5 |
| AnaemiaBlood and lymphatic system disorders | 1/3 | 4/7 | 1/3 | 1/4 | 3/4 | 3/4 | 0/3 | 0/7 | 1/3 | 1/6 | 2/3 | 6/14 | 1/5 |
| Oedema PeripheralGeneral disorders | 2/3 | 2/7 | 0/3 | 2/4 | 3/4 | 2/4 | 0/3 | 2/7 | 0/3 | 1/6 | 0/3 | 1/14 | 1/5 |
| HyponatraemiaMetabolism and nutrition disorders | 0/3 | 0/7 | 0/3 | 0/4 | 1/4 | 3/4 | 0/3 | 0/7 | 1/3 | 0/6 | 0/3 | 3/14 | 0/5 |
All enrolled participants.
| Age, Continuous(years) | DEC Arm A: 40 mg Cobimetinib + 200 mg Ipatasertib | DEC Arm A: 60 mg Cobimetinib + 200 mg Ipatasertib | DEC Arm A: 60 mg Cobimetinib + 300 mg Ipatasertib | DEC Arm A: 40 mg Cobimetinib + 400 mg Ipatasertib | DEC Arm B: 100 mg Cobimetinib + 200 mg Ipatasertib | DEC Arm B: 125 mg Cobimetinib + 200 mg Ipatasertib | DEC Arm B: 125 mg Cobimetinib + 400 mg Ipatasertib | DEC Arm B: 150 mg Cobimetinib + 300 mg Ipatasertib | DEC Arm B: 175 mg Cobimetinib + 200 mg Ipatasertib | DEC Arm B: 150 mg Cobimetinib + 200 mg Ipatasertib | DEC Arm B: 100 mg Cobimetinib + 400 mg Ipatasertib | Endometrial Carcinoma: 140 mg Cobimetinib + 300 mg Ipatasertib | Breast Cancer: 140 mg Cobimetinib + 300 mg Ipatasertib | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 61.0 ± 3.5 | 59.1 ± 8.7 | 58.3 ± 5.5 | 66.8 ± 16.5 | 62.3 ± 7.0 | 51.8 ± 10.9 | 59.0 ± 9.2 | 58.6 ± 11.9 | 61.0 ± 13.7 | 57.6 ± 10.9 | 52.7 ± 24.9 | 62.9 ± 8.7 | 49.0 ± 10.1 | 59.0 ± 11.0 |
| Sex: Female, Male(Participants) | DEC Arm A: 40 mg Cobimetinib + 200 mg Ipatasertib | DEC Arm A: 60 mg Cobimetinib + 200 mg Ipatasertib | DEC Arm A: 60 mg Cobimetinib + 300 mg Ipatasertib | DEC Arm A: 40 mg Cobimetinib + 400 mg Ipatasertib | DEC Arm B: 100 mg Cobimetinib + 200 mg Ipatasertib | DEC Arm B: 125 mg Cobimetinib + 200 mg Ipatasertib | DEC Arm B: 125 mg Cobimetinib + 400 mg Ipatasertib | DEC Arm B: 150 mg Cobimetinib + 300 mg Ipatasertib | DEC Arm B: 175 mg Cobimetinib + 200 mg Ipatasertib | DEC Arm B: 150 mg Cobimetinib + 200 mg Ipatasertib | DEC Arm B: 100 mg Cobimetinib + 400 mg Ipatasertib | Endometrial Carcinoma: 140 mg Cobimetinib + 300 mg Ipatasertib | Breast Cancer: 140 mg Cobimetinib + 300 mg Ipatasertib | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 2 | 4 | 1 | 3 | 3 | 4 | 2 | 3 | 2 | 4 | 1 | 14 | 5 | 48 |
| Male | 1 | 3 | 2 | 1 | 1 | 0 | 1 | 4 | 1 | 3 | 2 | 0 | 0 | 19 |
The record gives a start of Apr 2012, a primary completion of Jan 2015 and a completion of Jan 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2016, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ipatasertib · Cobimetinib